These educational Clinical Clips will spotlight the latest and most relevant clinical data in the advances in the treatment and management of non‐alcoholic steatohepatitis (NASH) with a series of ‘what you need to know in 5-minutes’ videos from data presented at the virtual International Liver Congress from June 23‐26.
ACPE Release Date: June 23, 2021
Expiration Date: May 31, 2022
This online educational activity is designed for gastroenterologists, hepatologists, endocrinologists and diabetologists involved in the screening and treatment of patients with or at risk for nonalcoholic steatohepatitis (NASH).
Upon completion of this enduring material, participants should be better able to:
In compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, it is the policy for all accreditors of this accredited continuing education activity as named above to ensure accuracy, balance, objectivity, independence, and scientific rigor in all their educational activities, and to commit to protecting learners from promotion, marketing, and commercial bias. All faculty, planners and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. This enduring material may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of the accredited providers and Practice Point Communications.
The accredited providers have mitigated and are disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
PLANNING COMMITTEE DISCLOSURE INFORMATION
Nothing to disclose
UNMC: Valeta Creason-Wahl; Heidi Keeler, PhD, RN; Marco Olivera-Martinez, MD; Renee Paulin, MSN, RN, CWOCN; Brenda Ram, CMP, CHCP
DU: Amy G. Woods, PharmD, MS Leadership
PPC: Peter Pinkowish; Chris Fleming; Ashley Richardson
Stephen Harrison, MD FACP, FAASLD
Peak Consulting, LLC
Advisory Board:89 Bio LTD, Akero Therapeutics, Altimmune, Arrowhead Pharmaceuticals, Axcella Health, Chronwell, Civi Biopharma, Cymabay Therapeutics, Echosens North America, Foresite Labs, Galectin Therapeutics, Galmed research & Dev LTD, Genfit Corp, Gilead Sciences, Hepion Pharmaceuticals, Hightide Therapeutics, Histonindex, Indalo Therapeutics, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Medpace, Metacrine, NGM Pharmaceuticals, Northsea Therapeutics, Novartis Pharmaceuticals, Novo Nordisk, Pathai, Poxel, Prometic, Ridgeline Pharmaceuticals, Sagimet Biosciences, Terns, Theratechnologies
Consultant: AgomAB, Akero Therapeutics, Altimmune, Axcella Health, Boston Pharmaceuticals, B Riley FBR, Canfite Pharmaceuticals, Civi Biopharma, Cymabay Therapeutics, Echosens North America, Enyo Pharma, Fibronostics, Foresite Labs,Fortress Biotech, Galectin Therapeutics, Genfit Corp, Gilead Sciences, GNS Healthcare, Hepion Pharmaceuticals, Hightide Therapeutics, Histonindex, Inipharm, Intercept Pharmaceuticals, Ionis, Kowa Research Institute, Madrigal Pharmaceuticals, Medpace, Metacrine, Microba PTY, NGM Pharmaceuticals, Northsea Therapeutics, Novartis Pharmaceuticals, Novo Nordisk, Nutrasource, Piper Sandler, Poxel, Prometic, Ridgeline Pharmaceuticals, Sagimet Biosciences, Sonic Incytes Medical Corp., Terns, Viking Therapeutics
Research Grant: Akero Therapeutics, Axcella Health, Cirius Therapeutics, Civi Biopharma, Cymabay Therapeutics, Enyo Pharma, Galectin Therapeutics, Galmed Research & Dev LTD, Genfit Corp, Gilead Sciences, Hepion Pharmaceuticals, Hightide Therapeutics, Intercept Pharmaceuticals, Madriga Pharmaceuticals, Metacrine, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis Pharmaceuticals, Novo Nordisk, Poxel, Sagimet Biosciences, Viking Therapeutics
Stock: Akero Therapeutics, Chronwell, Cirius Therapeutics, Galectin Therapeutics, Genfit Corp, Hepion Pharmaceuticals, Histoindex PTE, Metacrine, NGM Biopharmaceuticals, Northsea Therapeutics, Pathai
The University of Nebraska Medical Center, Duquesne University School of Pharmacy, and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Nebraska Medical Center, Duquesne University School of Pharmacy, and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
The University of Nebraska Medical Center, Duquesne University School of Pharmacy, and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
Supported by an independent educational grant from Theratechnologies
Launch Date: June 25, 2021
Release Date: June 23, 2021
Expiration Date: May 31, 2022